Safety of regular formoterol or salmeterol in adults with asthma: An overview of Cochrane reviews

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 2, 2014, Pages

  Cates, Christopher J ^a   Wieland, L Susan ^b   Oleszczuk, Marta ^c   Kew, Kayleigh M ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; FORMOTEROL FUMARATE; MOMETASONE FUROATE; PLACEBO; SALMETEROL; SALMETEROL XINAFOATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; SALBUTAMOL;

ASTHMA; COMBINATION DRUG THERAPY; DEATH; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADULT; DRUG COMBINATION; LITERATURE; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 84919938958     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010314.pub2     Document Type: Review

References (45)

1. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2]
2. Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD007694.pub2]
3. Cates CJ, Cates MJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD006923.pub3]
4. Cates CJ, Lasserson TJ. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD007695.pub3]
5. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD006922.pub3]
6. Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD006924.pub3]
7. Altman DG, Bland JM. Statistics notes: interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219.
8. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372(9643):1107-19. [1474-547X: (Electronic)]
9. Boushey HA, Holtzman MJ, Sheller JR, Nadel JA. Bronchial hyperreactivity. American Review of Respiratory Disease 1980;121(2):389-413. [(Print)]
10. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2007;26(1):53-77. [0277-6715: (Print)]
11. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91.
12. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306(6884):1034-7.
13. Cates CJ. Assessing the risks of serious adverse events from regular long-acting beta-agonists for adults and children with asthma. MD Thesis, University of Cambridge, 2011.
14. Cates CJ, Oleszczuk M, Stovold E, Wieland LS. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD010005]
15. Chan A-W, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291(20):2457-65.
16. Chan A-W, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Canadian Medical Association Journal 2004;171(7):735-40.
17. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. The New England Journal of Medicine 2011;364(26):2473-5.
18. Cipriani A, Higgins JPT, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Annals of Internal Medicine 2013;159:130-7.
19. Cockcroft D. Airway hyper-responsiveness as a determinant of the early asthmatic response to inhaled allergen. Journal of Asthma 2006;43(3):175-8.
20. Corren J, Mansfield LE, Pertseva T, Blahzko V, Kaiser K. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Respiratory Medicine 2013;107:180-95.
21. GINA. Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_March13.pdf (accessed 9 February 2013).
22. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285(4):437-43. [0098-7484: (Print)]
23. Ioannidis JPA, Evans SJW, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8.
24. Lougheed MD, Lemiere C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, et al. Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada. Canadian Respiratory Journal 2010;17(2):57-8.
25. Matsunaga K, Kawabata H, Hirano T, Sugiura H, Minakata Y, Ichinose M. Difference in time-course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology & Therapeutics 2013;26:189-94.
26. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting β2-adrenergic receptor agonists. Pediatrics 2011;128(5):e1147-54.
27. Nathan R A, D'Urzo A, Blazhko V, Kaiser K. Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial. BMC Pulmonary Medicine 2012;12:67.
28. AstraZeneca. A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents. http://clinicaltrials.gov/show/NCT01444430 (accessed June 2012).
29. GlaxoSmithKline. 6-Month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old (VESTRI). http://clinicaltrials.gov/show/NCT01462344 (accessed 29 June 2012).
30. Merck. A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3) (SPIRO). http://clinicaltrials.gov/ct2/show/NCT01471340 (accessed June 2012).
31. GlaxoSmithKline. SAS115359: A 6-Month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (AUSTRI). http://clinicaltrials.gov/show/NCT01475721 (accessed June 2012).
32. Pearlman DS, LaForce CF, Kaiser K. Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clinical Therapeutics 2013;35:950-66.
33. Phillips GD, Finnerty JP, Holgate ST. Comparative protective effect of the inhaled beta-2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma. Journal of Allergy and Clinical Immunology 1990;85(4):755-62.
34. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) 5.2. 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
35. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Annals of Internal Medicine 2006;144(12):904-12.
36. Sears MR, Radner F. Safety of formoterol in asthma clinical trials: an update. European Respiratory Journal Epub 30 May 2013. [DOI: 10.1183/09031936.00004713]
37. Shea B, Grimshaw J, Wells G, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;7:10. [DOI: 10.1186/1471-2288-7-10]
38. Scottish Intercollegiate Guidelines Network/British Thoracic Society. British guideline on the management of asthma: a national clinical guideline 2008 (revised January 2012). http://www.sign.ac.uk/guidelines/fulltext/101/. Edinburgh: Scottish Intercollegiate Guidelines Network, (accessed 9 February 2013).
39. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26.
40. Stirbulov R, Fritscher CC, Pizzichini E, Pizzichini MMM. Evaluation of the efficacy and safety of a fixed-dose, single-capsule budesonide-formoterol combination in uncontrolled asthma: a randomized, double-blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia 2012;38:431-7.
41. Tattersfield AE. Current issues with beta2-adrenoceptor agonists: historical background. Clinical Reviews in Allergy and Immunology 2006;31(2-3):107-18.
42. Van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. European Respiratory Journal 1996;9(8):1684-8.
43. Cates CJ. Visual Rx 3.0. www.nntonline.net/visualrx/(September 2008).
44. Weinberger M, Abu-Hasan M. Life threatening asthma during treatment with salmeterol. New England Journal of Medicine 2006;355:852-3.
45. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363(9418):1341-5.